Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

A person with one abnormal hemoglobin gene and one typical hemoglobin ... The most severe form of SCD is sickle cell anemia. If parents are considering having a child and are concerned about ...

The hemoglobin elevating agent is being developed for the treatment of anemia associated with multiple diseases.

Sickle Cell Disease Market Size Was Valued at USD 2.40 Billion in 2023, and is Projected to Reach USD 12.38 Billion by 2032, ...

Ghana on Tuesday unveiled a National Sickle Cell Disease (SCD) Strategy aimed at improving both preventive and treatment services for the condition.

Editas Medicine announced proof-of-concept data for a gene-editing approach for sickle cell disease that doesn't need a stem ...

The FDA granted orphan drug status to Kind Pharmaceuticals' investigational oral small molecule AND017 to treat SCD.

Nobel Prize winner and UC Berkeley professor Jennifer Doudna presented developments on her gene research at a UC Santa Barbara Arts & Lectures event on Oct. 22.

The Pt Deendayal Upadhyay Memorial Health Sciences and Ayush University collaborates with CSIR-CCMB to enhance sickle cell anemia diagnosis and genetic research, improving public health outcomes in ...

According to Uganda's Ministry of Health, around 250,000 people in the country live with sickle cell disease, including an estimated 20,000 to 25,000 babies ...

Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session –– Tebapivat Phase 1 ...

Stay updated on Beam Therapeutics Inc.'s latest advancements in Sickle Cell Disease and alpha-1 antitrypsin deficiency treatments. Click for my BEAM stock update.